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Abstract: - An outbreak of a novel virus, SARS-CoV-2, reported in Wuhan, China in December 2019, caused COVID-19 which 
led the WHO to declare a state of pandemic due to its high morbidity rates. More than 300 clinical trials have emerged in determining 
potential sources of treatment. One of the most studied drugs is Favipiravir, an antiviral agent known for treating influenza, which 
is said to exhibit effects in targeting SARS-CoV-2. Uric acid elevation is one of the adverse effects that may be of clinical importance 
upon administration to patients with hyperuricemia, impaired kidneys, undertaking medications and with history of gout due to 
redevelopment of disease. This study aimed to provide a valid estimate of Favipiravir’s potency by determining the proportion of 
patients who were tested negative for COVID-19 after 10 days and to review the occurrence of uric acid elevation. A search method 
with inclusion and exclusion criteria was utilized for browsing online databases, namely PubMed, Science Direct, and Embase. Two 
data mining processes were done and analyses for each objective were made using Mantel-Haenszel Fixed Effects Odd Ratio and 
Forest Plot. Incidence of viral negativity after 10 days with OR 1.76[0.90, 3.43] and overall effect Z of 1.67 (P = 0.10) showed no 
statistical significance while occurrence of uric acid elevation with OR 30.69 [1.78, 528.82] and overall effect Z of 2.36 (P = 0.02) 
showed statistical significance. In conclusion, administration of Favipiravir has no effect on the clearance of SARS-CoV-2 after 10 
days and can cause an increase in uric acid levels.  
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I.    INTRODUCTION 
SARS-CoV-2 is a virus responsible for this recent and ongoing 
worldwide COVID-19 pandemic. It started last December 2019 
as an initial outbreak at the Seafood market in Wuhan City 
China. Due to the growing concerns regarding social, economic 
and health impacts, scientists and health practitioners all over 
the world are in search of treatments in combating this disease. 
With this, more than 300 clinical trials have emerged and 
certain agents are being studied based on in vitro or 
observational studies [1].  
A widely known antiviral agent in treating strains of Influenza 






in combatting COVID-19 shown in several clinical trials. 
Favipiravir, developed by Toyama Chemical Fujifilm, acts as a 
matching substrate to RdRp (RNA dependent RNA 
polymerase) causing inhibition to the replication process of 
RNAs [2]. Clinical outcomes of several conducted clinical trials 
have shown Favipiravir to exhibit increased potency than 
Lopinavir and Ritonavir [3], decreased the symptoms of 
pneumonia [4], and decreased the incidence of fever and cough 
and possess a higher clinical recovery rate by 7 days [5]. 
Favipiravir combined with other drugs such as with the addition 
of Tocilizumab improved pulmonary inflammation [5] and a 
reduction in mortality rate and inhibition of hypercoagulopathy 
is seen with the addition of Nafamostat mesylate [6]. As 
promising as it may seem, the appearance of some adverse 
effects that can cause clinical significance are inevitable. Some 
of the reported clinical adverse effects of Favipiravir are as 
follows; diarrhea and liver injury [7], prolongation of QT 
intervals and TdP (Torsade de Pointes) [8], teratogenicity, 
increased analytes such as ALT, AST, GGT, blood triglycerides 
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and uric acid, and decreased neutrophil and WBC count [9]. 
Studies made by Agrawal, Raju, and Udwadia (2020) [9], and 
Pilkington, Pepperrell, and Hill's (2020) [10] have found that 
administration of FVP monotherapy or polytherapy can cause 
uric acid elevation that can be of clinical value for establishing 
treatments. With this, uric acid elevation is given importance 
due to its frequent occurrence and the possibility of a 
redevelopment of hyperuricemia and acute gouty arthritis [11]. 
In the Philippines, PGH and Sta. Ana Hospitals are two from 
several hospitals participating in FVP trials. As of January 
2021, 37 COVID-19 patients with non-severe pneumonia have 
enrolled in these clinical trials which are still going on [12].  
 
This study aims to provide a comprehensive synthesis regarding 
the usage of Favipiravir as a monotherapy in terms of potency 
and the capability to cause uric acid elevation. The study 
utilizes trials using a   Favipiravir monotherapy and a specific 
dose of 1800 mg twice on the 1st day followed by 800 mg on 
subsequent days in providing a valid estimate of Favipiravir’s 
potency by the proportion of patients who were tested negative 
after the treatment with Favipiravir after 10 days and reviewing 
the occurrence of uric acid elevation in a specific dosage for 
Favipiravir-treated patients. 
II.    METHODS 
  A. Introduction 
 
This study is a meta-analysis on the potency of Favipiravir, as 
a treatment modality to SARS-CoV-2 intended for the patients 
infected with COVID-19 and its effect on uric acid levels. This 
study utilized a quantitative research design, which derived data 
from published peer-reviewed journal articles to synthesize 
new data via meta-analysis. 
 
A search engine was utilized, and a search engine is defined as 
an information retrieval system designed for use on collections 
with massive amounts of text [13]. The data came from peer-
reviewed journal articles from the following databases: 
PubMed, Science Direct, Cochrane Library, PsycInfo, Embase, 
and Web of Science. The articles were screened based on the 
inclusion and exclusion criteria as seen in Table 1. A step-by-
step guide regarding the conduct of a systematic review and 
meta-analysis by the University of Edinburgh’s Centre for 




Fig.1. A Flowchart summarizing the Data Mining Method. 
 
  B. The Selection Criteria 
  
All the results were manually screened based on the inclusion 
and exclusion criteria, and the studies which passed the 
inclusion criteria were collected. The studies were sorted 
according to their relevance in answering the research problems 
and information was extracted based on the values needed for 
the planned statistical analysis.  
  
The journal articles that were utilized in this study had a 
research design of either descriptive, comparative, 
correlational, or quasi-experimental. Each set of studies with 
the same research design had different functions in answering 
specific objectives. Studies with a descriptive research design 
were used in finding out the estimated Favipiravir’s potency in 
curing COVID-19 and its adverse effects. Articles with a 
comparative research design of Favipiravir with other antiviral 
drugs were used to gather data for the proportion of patients 
who were tested negative after the treatment with Favipiravir, 
and how many patients exhibited uric acid elevations upon the 
treatment with Favipiravir. Studies with a correlational research 
design were also used in assessing the relationship between the 
concentration of Favipiravir and hyperuricemia. They were also 
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used in assessing the concentration of Favipiravir in relation to 
exhibiting better clinical outcomes. Lastly, studies with a quasi-
experimental research design that utilized clinical trials of 
Favipiravir treatments alone and/or in combination therapy 
with other antiviral drugs were used to determine and evaluate 
the uric acid elevation and clinical outcomes of Favipiravir 
treatment. The target population or subjects are patients 
infected with the COVID-19 disease. 
 
Since the study is a systematic review, the inclusion and 
exclusion criteria were aimed in the studies included in the 
review. Among the inclusion criteria are the qualities of articles 
being published by more than 3 authors and with a publication 
date from December 2019 to December 2020, containing 
clinical data on the direct application of Favipiravir as the mode 
of treatment for SARS-CoV-2. The studies' subjects would be 
patients with mild including asymptomatic to severe symptoms 
of COVID-19 infection, aged 18-85 years old, and critically ill 
patients with COVID-19 infection, aged 18-85 years old. The 
included outcomes that were assessed in the studies are the 
number of patients who were tested negative after the treatment 
with Favipiravir and uric acid elevation occurrence.  
 
Table.1. Summary of the Inclusion and Exclusion Criteria. 
 
Among the exclusion criteria would be studies which were 
published by less than 3 authors or the date of publication was 
until June 2015, studies with immunocompromised patients, 
and studies which have reported the presence of a placebo 
response that may have contaminated their results with bias. 
Furthermore, the patients' expectation is a major mediator of the 
placebo response [15]. Aside from the mentioned qualities, 
studies from the following search engines were not included: 
Wikipedia, Quora, blog posts, and unofficial websites. 
 
 
Fig.2. Schematic Diagram of the Data Mining Process using the 
Search Engines based on the Inclusion and Exclusion Criteria 
 
  C. Data extraction 
 The review authors used a data extraction form constructed 
using Microsoft Excel 2019. The data extraction of all included 
studies was independently performed by two review authors 
(M.I.A.S., A.M.V.S.). The following study characteristics were 
collected: study information (author, year, study design, 
country), target population (age group, number, symptom 
severity, COVID-19 status), and relevant parameters (number 
of patients who tested negative for COVID-19 after treatment 
with Favipiravir for 10 days, number of patients whose uric acid 
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levels were elevated upon the administration of Favipiravir). 
Disagreements between the two review authors concerning the 
inclusions, data extraction, and quality assessment were 
resolved by a third reviewer (L.J.D.R.). 
  
  D. Quality Assessment 
Two review authors (I.M.B.S., M.N.L.S.) independently 
evaluated the methodological quality using the Revised 
Cochrane risk-of-bias tool for randomized trials (RoB 2) for all 
included RCT studies. RoB 2 includes a framework for 
determining the risk of bias in the results and findings of any 
type of a randomized clinical trial [16]. This assessment is 
distinctly utilized for a single trial result which corresponds to 
an estimate of the relative effect of two interventions, namely 
the experimental intervention and comparator intervention or 
intervention strategies on a particular outcome. RoB 2 follows 
a five-domain structure through which bias might be introduced 
into the result. The JBI Critical Appraisal Checklist was also 
used for case reports, since it is more appropriate than RoB 2 
for assessing the quality and extent of bias in the design, 
conduct and analysis of case reports [17].  Disagreements 
between the two review authors were resolved by a third 
reviewer (R.J.P.T.). 
  
  E. Statistical Analysis  
The quality of the data collected from the clinical trials were 
assessed through the Revised Cochrane risk-of-bias tool for 
randomized trials which measured the risk of bias from the data 
gathered. The data was compared and represented through the 
Forest Plot and Mantel-Haenszel Fixed-Effects Odds Ratio to 
visualize significant differences within the gathered data. 
Forest plot. The data analysis used to elaborate the data 
provided by the following three clinical trials namely Doi et al. 
(2020), Ivashchenko et al. (2020), and Udwadia et al. (2020) 
were represented graphically and were shown and illustrated for 
the relationship between the variables [18, 19, 20]. Presented 
were two zones wherein the left zone is a descriptive area of 
each study where it contains the list of randomized controlled 
trials along with the event rates that are listed within the criteria 
of the meta-analysis. The right zone, on the other hand, is 
presented graphically wherein the graph represents the measure 
of effect or the odds ratio for the studies by integrating 
confidence intervals represented by graphical horizontal lines. 
Furthermore, a vertical line is also present which represents the 
“line of null-effect” wherein it is placed at a value where there 
is no association between an outcome and exposure or no 
difference between the two interventions. If the confidence 
intervals for the trials cross the vertical line, it means that the 
null present within the 95% confidence interval implies that the 
study result is indeed the null value, therefore, the study did not 
observe a statistically significant difference between the control 
and the treatment groups for the individual study. 
Mantel-Haenszel Fixed-Effects Odds Ratio.  The Mantel-
Haenszel Fixed-Effects Odds Ratio evaluated the association 
between the recorded outcome and its exposure that were 
shown statistically in this study that measured the effectiveness 
of the clinical trials of Doi et al. (2020), Ivashchenko et al. 
(2020), and Udwadia et al. (2020), which were also included 
further in the forest plot presentation [18, 19, 20]. The odds 
ratio was utilized to determine whether a particular exposure is 
a risk factor for a particular outcome and compared the 
magnitude of various risk factors for that outcome. 
Accordingly, if the odds ratio is equal to 1, then the exposure 
does not affect the odds of the outcome. If the odds ratio is less 
than 1, then the exposure is associated with lower odds of the 
outcome. If the odds ratio is greater than 1, then the exposure is 
associated with higher odds of the outcome. 
                 
Table.2. Mantel-Haenszel Fixed-Effects Odds Ratio Sample Table 




Control c d 
 





When data is scarce, in times when the event risks are too low 
or the study size is limited in number, the estimates of certain 
standard errors used in the inverse-variance methods may have 
a poor result [21]. The Mantel-Haenszel method is preferred 
generally to the inverse variance method in fixed-effect meta-
analyses. Mantel-Haenszel methods are fixed-effect meta-
analysis methods using a different weighting scheme that 
depends on which effect measure is being used. 
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 The larger the weight given to the specific study, the more it 
would contribute to the weighted average, wherein each given 







The summary log odds ratio has standard error given by 



































                           III.    RESULTS AND DISCUSSION 
A. Data Mining Results of Viral Clearance 
 
Out of initially 1,384 studies, only 3 studies qualified based on 
the selection criteria and were further assessed based on the 
Revised Cochrane risk-of-bias tool for randomized trials (RoB 




Fig.3. The PRISMA 2009 Flow Diagram of collected studies for 
estimating Favipiravir’s potency by the proportion of patients who 
were tested negative after treatment with Favipiravir after 10 days. 
B. Quality Assessment of Viral Clearance 
 
The included studies were subjected to the quality assessment 
tool, specifically the Revised Cochrane risk-of-bias tool for 
randomized trials (RoB 2) as seen in Table 3. 
 
Table.3. Quality Assessment of the Studies qualified for estimating 
Favipiravir’s potency by the proportion of patients who tested 
negative after the treatment with Favipiravir after 10 days (RoB 2). 
 
 
All the included studies were randomized and open-label trials. 
The final judgements for the risk of bias are RCT-1 is high risk, 
RCT-2 has some concerns, and RCT-3 has some concerns. The 
quality assessments were done by 2 independent authors, 
namely I.M.B.S., and M.N.L.S., and any conflicts were 
resolved by a 3rd author, namely R.J.P.T. To resolve a conflict, 
the 3rd author made an independent review, based on the full 
guide for using the RoB 2 tool. The RoB 2 tool has five 
domains, and in RCT-2 in Table 3, the two initial review 
authors disagreed on the first and fourth domains. This was 
resolved by R.J.P.T. for finalization. The study by Udwadia et 
al. (2020) and Doi et al. (2020) were both used in estimating 
Favipiravir’s potency by the proportion of patients who were 
tested negative after the treatment with Favipiravir after 10 days 
and reviewing the occurrence of uric acid elevation in COVID-
19 patients treated with Favipiravir [18, 20]. 
 
C. Data Mining Results of Uric Acid 
 
Out of initially 1,389 studies, only 4 studies qualified based on 
the selection criteria and were further assessed based on RoB 2 
and JBI Critical Appraisal Checklist for Case Reports, and only 
2 studies were qualified for the meta-analysis, since the other 2 
studies were case reports as seen in Figure 4. 
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Fig.4. The PRISMA 2009 Flow Diagram of collected studies for 
reviewing the occurrence of uric acid elevation in COVID-19 
patients who were treated with Favipiravir. 
 
D. Quality Assessment of Uric Acid 
 
The included studies were subjected to the quality assessment 
tools such as the Revised Cochrane risk-of-bias tool for 
randomized trials (RoB 2) for randomized clinical trials and JBI 
Critical Appraisal Checklist for Case Reports as seen in Table 
4. 
Table. 4. Summary of the Quality Assessment of the Studies qualified 
for reviewing the Occurrence of Uric Acid Elevation in COVID-19 
patients treated with Favipiravir, based on RoB 2 
 
 
The two included studies were randomized and open-label 
trials. The final judgements for the risk of bias are RCT-1 is 
high risk and RCT-2 has some concerns. The quality 
assessments were also done by 2 independent authors, namely 
I.M.B.S., and M.N.L.S., and any conflicts were resolved by a 
3rd author, namely R.J.P.T. To resolve a conflict, the 3rd 
author, R.J.P.T. made an independent review, based on the full 
guide for using the RoB 2 tool. 
 
Table.5. Summary of the Quality Assessment of the Studies qualified 
for reviewing the Occurrence of Uric Acid Elevation in COVID-19 
patients treated with Favipiravir, based on the JBI Critical Appraisal 
Checklist for Case Reports. 
 
 
A separate quality assessment tool was used for evaluating case 
report studies, since the RoB 2 tool was not appropriate for 
evaluating case reports and it is most appropriately used for 
randomized clinical trials. For evaluating the case reports, the 
JBI Critical Appraisal Checklist for Case Reports was utilized, 
and the overall appraisal was to include both case reports 
collected. There were no discrepancies between the review 
authors. Both case reports were then used in reviewing the 
occurrence of uric acid elevation in COVID-19 patients treated 




Upon the implementation of the data mining process described 
in Figure 1, the following data were collected for estimating 
Favipiravir’s potency by the proportion of patients who were 
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Table.6. Summary of the Data collected from the studies qualified for 
estimating Favipiravir’s potency by the proportion of patients who 
were tested negative after the treatment with Favipiravir after 10 days 
 
 
All the included studies reported similar doses of Favipiravir, 
which is 1,800 mg twice on the first day, followed by 800 mg 
twice on the subsequent days until the 14th day. A meta-
analysis via forest plot was conducted to interpret the data as 
seen in Table 6. 
 
 
Fig.5. Forest Plot of Incidence of Viral Negativity after 10 days of 
taking Favipiravir. 
 
Figure 5 above presents the forest plot of the odds ratio of viral 
negativity when taking Favipiravir in treating for COVID-19. 
Doi et al. (2020) noted that 31 out of 36 patients who have taken 
Favipiravir are cleared from COVID-19 after 10 days of 
treatment. The study did not have a control group, thus, Doi et 
al. (2020) did not report the corresponding odds ratio for viral 
clearance [18]. Meanwhile, in the study of Ivashchenko (2020), 
19 out of 20 patients or 95% under the treatment group were 
cleared from COVID-19 after 10 days of treatment compared 
to only 16 out of 20 patients or 80% in the control group. The 
Mantel Haenszel fixed-effects odds ratio is estimated to be 4.75 
(95% CI: [0.48, 46.91]) for the study of Ivashchenko (2020) 
[19]. This indicates that the odds of being viral negative after 
10 days of treatment with Favipiravir is 375% higher compared 
to the odds of being viral negative if only standard care 
treatment was done to the patient. In addition, Udwadia et al 
(2020) reported that 53 out of 72 patients or 73.6% treated with 
Favipiravir were cleared from COVID-19 after 10 days of 
treatment while 48 out of 75 patients or 64% in the control 
group were cleared from COVID-19 after 10 days [20]. The 
estimated odds ratio is 1.57 (95% CI: [0.78, 3.18]) which means 
that the odds of being viral negative after 10 days is 57% higher 
for those treated with Favipiravir compared to those who are 
left untreated. 
 
The pooled odds ratio is 1.76 with a 95% confidence interval of 
0.90 to 3.43. This means that there is a 75% increase in the odds 
of being viral negative after 10 days if the patient is treated with 
Favipiravir compared to those who are not treated with 
Favipiravir. However, since the confidence interval contains 
the value of 1.0, the estimated odds ratio is not statistically 
significant at a 95% confidence level. This means that there is 
no sufficient evidence from the included studies to conclude 
that Favipiravir helps in the treatment of COVID-19 patients. 
 
On the other hand, to review the occurrence of uric acid 
elevation in COVID-19 patients treated with Favipiravir, 
another data mining process was conducted, and the following 
data were collected from the included studies. 
 
Table.7. Summary of the Data Collected from the Studies qualified for 
reviewing the Occurrence of Uric Acid Elevation in COVID-19 
patients who were treated with Favipiravir 
 
 
All the included studies reported similar doses of Favipiravir, 
which is 1,800 mg twice on the first day, followed by 800 mg 
twice on the subsequent days as seen in Table 7.  
 
 
Fig.6. Forest Plot of Incidence of Prevalence of Uric Acid Elevation 
Associated with Favipiravir. 
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Figure 6 presents the forest plot of the prevalence of uric acid 
elevation on COVID-19 patients treated with Favipiravir. Doi 
et al. (2020) reported a total of 69 out of 82 patients (84.1%) 
have experienced an increase in uric acid concentrations after 
taking Favipiravir [18]. Odds ratios are not reported for Doi et 
al. (2020) since their study did not have a control group. For 
Udwadia et al. (2020), only 12 out of 73 patients or 16.4% have 
experienced an increase in uric acid levels while none of the 
patients in the control group have experienced an increase in 
uric acid levels [20]. The risk estimate with 95% CI is at 30.69 
[1.78, 528.82]. For the overall meta-analysis, the total risk 
estimate with 95% CI is at 30.69 [1.78, 528.82]. Heterogeneity 
is not applicable since only one study is eligible for estimation. 
The test for overall effect is at Z = 2.36 (P = 0.02). Also, the 
confidence interval does not contain the value of 1.0, the 
estimated odds ratio is statistically significant at a 95% 
confidence level. With this, it shows that there is a significant 
correlation between the occurrence of uric acid and its 
administration with FVP. Furthermore, 2 case studies/reports 
were reported that observed uric acid elevation. These case 
studies were excluded in the meta-analysis as it is not 
considered as a representative sample. A case study by Hase et 
al. (2020) has reported a 42-year-old man with positive 
COVID-19 disease that experienced uric acid elevation upon 
his 13th day of administration of FVP at a dose of 1800 mg and 
then later developed into acute gouty arthritis on day 15th of 
administration of FVP [11]. Another case study by Takoi et al. 
(2020) also reported a uric acid elevation in a 42-year-old man 
with positive COVID-19 infection upon administration of 




The findings of the meta-analysis for estimating Favipiravir’s 
potency by the proportion of patients who were tested negative 
after the treatment with Favipiravir after 10 days were not 
statistically significant since the confidence interval contains a 
value of 1. This is supported by the forest plot wherein the 
overall odds ratio of the studies is 1.76 (95% CI 0.90-3.43), 
which indicates that there is an increase in the viral negativity 
after 10 days of taking Favipiravir. However, with a confidence 
interval of 1, this indicates that the difference in the viral 
negativity of the experiment and control group is insignificant 
at a 95% confidence level and therefore, both treatments have 
high probability of viral negativity after 10 days. With that, the 
statistical results suggest that it may not only be Favipiravir 
which is the prime cause of viral negativity and that there is no 
sufficient evidence that it helps with treatment of COVID-19 
patients. Favipiravir’s capability to induce viral negativity in 
COVID-19 infected patients was not proven in this study due 
to the lack of statistical significance, despite its mechanism of 
action, which is inhibiting the RNA-dependent RNA 
polymerase (RdRp) of RNA viruses, one of which is SARS-
CoV-2. Favipiravir possesses a strong binding affinity to the 
RdRp complex of SARS-CoV-2 [23], and this is important 
because RdRp plays an important role in the replication or 
transcription of SARS-CoV-2 [24]. The lack of statistical 
significance may be attributed to the closeness of the number of 
patients who tested negative for COVID-19 between the 
treatment groups and the control groups, which indicates the 
independence of the viral clearance from the usage of 
Favipiravir. This is further supported by Lou et al. (2020) which 
reported that Favipiravir’s antiviral activity was not as effective 
as the previously reported in vitro half maximal effective 
concentration by Wang et al. (2020) of 61.88 μM, since 
Favipiravir was only able to inhibit less than 50% of SARS-
CoV-2 in patients, even in concentrations up to 100 μM [25, 
26]. In the study by Lou et al. (2020), the median time that 
Favipiravir can cause a clinical improvement was 14 days, 
while their control group achieved clinical improvement in 15 
days [25], which may further indicate the independence of viral 
clearance from Favipiravir, since the difference is small. 
 
On the other hand, the findings of the meta-analysis on the 
prevalence of uric acid elevation in association to the 
administration of FVP were statistically significant although a 
best estimate cannot be provided since only one study was able 
to be quantified due to the lack of control in the study conducted 
by Doi et al. (2020) [18]. Both participants in this study 
reported no history of gout and hyperuricemia. Udwadia et al. 
(2020) have observed that uric acid elevation is rather dose 
dependent since no incremental increase in serum uric acid was 
observed after Day 5 to 10 wherein the dosage was reduced to 
800 mg from the initial dose of 1800 mg [20]. The significant 
correlation of the prevalence of uric acid elevation with FVP 
was further portrayed in the forest plot where the horizontal line 
that signifies the confidence interval of the study lies beyond 
the value of 1.0, which indicates the statistically significance of 
the estimated odds ratio at a 95% confidence level. Since there 
is only one qualified study, heterogeneity was not recorded. 
This is supported by the total odds ratio of 30.69 [1.78, 528.82] 
which means the probability of uric acid elevation with 
administration of FVP is statistically significant. To further 
support the occurrence of uric acid elevation in relation to FVP 
INTERNATIONAL JOURNAL OF PROGRESSIVE RESEARCH IN SCIENCE AND ENGINEERING, VOL.2, NO.8, AUGUST 2021. 
 
  
LEILA JAN R. DIMAIWAT., et.al: META-ANALYSIS ON THE POTENCY OF FAVIPIRAVIR AGAINST SARS-COV-2 AND ITS EFFECT 
ON URIC ACID LEVELS 
531 
 
administration, a case report by Hase et al. (2020) reported a 
42-year-old man with a medical history of hyperuricemia, gout 
attack, type 2 diabetes, and hyperlipidemia [11]. The patient 
was administered with FVP twice daily with a dosage of 1800 
mg on the 3rd day upon admission and was later reduced to 800 
mg taken twice a day. It was reported that the patient 
experienced increased levels of uric acid after administration of 
FVP and the development of acute gouty arthritis due to the 
longer duration of FVP administration. With this, it was treated 
with non-steroidal anti-inflammatory drugs that later on 
improved the patient’s condition which made him recover. 
Another case study by Takoi et al. (2020) reported 1 out of 2 
patients developed an increased uric acid level [22]. The patient 
was reported to be taking febuxostat for hyperuricemia but 
upon FVP administration with a dosage of 1800 mg taken twice 
daily on the 1st day upon admission, the uric acid level of the 
patient was elevated. Thus, the elevated uric acid level of the 
patient was upon FVP administration. To conclude, patients 
with or without symptoms of hyperuricemia and gout still 
developed an increase in serum uric acid levels upon FVP 
administration. 
 
As mentioned, one of the known adverse effects caused by 
Favipiravir is the increase of uric acid due to the mechanism of 
FVP in inhibiting the OAT1 and OAT3 which are transporter 
anions important for the tubular secretion of uric acid. In line 
with this, FVP hydroxide promotes the reuptake of uric acid. 
Thus, impaired excretion of uric acid in the urine causes the 
serum uric acid levels to accumulate in the blood [11, 27]. With 
this, it supports the findings of this research that FVP can 
increase blood uric acid upon its administration and can lead to 
the reappearance of the previous clinically significant medical 
illnesses such as acute gouty arthritis and hyperuricemia. Upon 
observation, the reappearance of these medical illnesses did not 
result in any deaths in the reported case studies. In addition to 
this, since it has been reported that Favipiravir does not cause 
any severe illness and severe side effects, Favipiravir can still 
be used in treating patients with COVID-19. However, proper 
usage in dosing regimens and awareness of its reported side 
effects must be observed. Overall, with the use of the forest 
plot, the predominating results of the studies show that 
Favipiravir’s viral negativity induction is insignificant while its 
capability for uric acid elevation is significant. In the analyzed 
studies, both the control and experimental (Favipiravir) group 
present a high probability of inducing viral negativity in 
COVID-19 patients after 10 days of treatment. In assessing the 
effect of FVP on uric acid levels, the analyzed studies showed 
that the incorporation of this drug in COVID19 treatment can 
increase serum uric acid levels without causing severe illness 




Interpretation of the results of these meta-analyses has its 
limitations. The limitations of our study include: (1) There is 
limited data on the treatment of Favipiravir and its effects on 
COVID-19 patients, thus, the study is not of a comprehensive 
evaluation of data and analysis; (2) The overall effect of the 
efficacy and safety of Favipiravir in combination with other 
antiviral drugs is not included in the analysis; (3) The severity 
of uric acid elevation in the administration of oral vs 
intravenous FVP is not measured; and (4) Only a single dosing 
regimen was used to measure the outcomes. 
                                       IV.   CONCLUSION 
In conclusion, Favipiravir’s potency as regards to the 
proportion of negatively tested patients after administration of 
the drug, for a duration of 10 days, showed no statistical 
significance. Favipiravir's lack of capacity to induce viral 
negativity in patients infected with COVID-19 did not exhibit 
consistency with its inhibitory effect on the RNA-dependent 
RNA polymerase (RdRp) of SARS-CoV-2 [23].  FVP can also 
induce an increase in the blood uric acid levels upon 
administration and may lead to the re-emergence of diseases 
associated with uric acid levels, specifically acute gouty 
arthritis and hyperuricemia. The reappearance of diseases had 
no reports of death and severe side effects of FVP in the 
included studies. The 4 studies that show uric acid elevation 
gives us evidence about the occurrence of the adverse effect. 
However, these findings are inconclusive in terms of frequency 
of occurrence due to the scarcity of evidence. Although there 
was an observed statistical significance between the occurrence 
of uric acid elevation with respect to different dosages of 
Favipiravir, this study was not able to stipulate an estimate of 
the relationship between the uric acid elevation and the 
administration of FVP due to insufficient studies that qualified 
this meta-analysis’ criteria. 
 
This study may impart an extensive knowledge on students, 
researchers, as well as doctors, about the potency of Favipiravir 
in connection to the number of negatively tested patients after 
a duration of 10 days and its correlation to blood uric acid 
levels. With this, physicians, most especially the frontliners in 
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this time of pandemic, can widen their knowledge about the 
drug and expand their options on the possible treatments for 
COVID-19 patients.  More information about Favipiravir can 
also help patients in exercising their right to choose what 
treatment they want by being critical of Favipiravir’s safety and 
efficacy on the basis of this study’s findings.  Teaching 
personnel may incorporate this study and other studies 
concerning antivirals for SARS-CoV-2 in their course plans. 
This research may also serve as a reference material not only to 
students but for future researchers as a source of evidence that 
can support their studies. Information on the proper assessment 
done in clinical trials like this research, specifically finding the 
right parameters for the potency of the drug while taking into 
consideration the capacity of the body to tolerate the drug's 
action. And lastly, may this study be of high relevance in the 
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